ARCHIVES

FDA Approves Gemzar For Ovarian Cancer, Contradicting ODAC Recommendation; Continues Agency Trend to Recognize Progression-Free Survival As An Endpoint.

This article is from The Cancer Letter archive.

Vol. 32 No. 28 | July 21, 2006

Download PDF Visit The Full Archive

Related Articles

DCPC Advisors Okay Continuation of Children’s Diet Study

January 31, 1992

Healy Sworn In, Calls For ‘Operation Bethesda Storm’

July 12, 1991

In Brief: ONS Invites Proposals For Research On Hazards Of Chemotherapy; UTSCC Adopts Code Of Ethics

August 31, 1984

Trapido To Lead NCI’s Epidemiology Program.

July 26, 2002

FDA Orders More Changes In ESA Label,

August 8, 2008

ACS President Lawrence Emphasizes Prevention Gains Since 1971

April 10, 1992